---
title: "Esophageal Cancer Management"
subtitle: "Levine Cancer Institute"
author: "Jonathan C Salo MD"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer-logo-link: "https://gisurgonc.github.io/talks/"
    #background-image: "images/lci_wfu_surgery_background.png"
    css: "lci_styles.css"
    theme: [simple, lci.scss]
    echo: false
title-slide-attributes: 
  data-background-image: "images/lci_wfu_surgery_background.png"
  data-background-size: contain
  data-background-opacity: "number" # e.g., "0.5" for 50% opacity
  #nanotes_pdf: default
  pdf:
    includes:
      in-header: "preamble.tex"
  #pptx: 
    #reference-doc: talks.pptx
filters:
  - reveal-header
editor: visual
bibliography: zotero.bib
# Ideal image size 1600 x 770
---

## Esophageal Cancer Treatment Categories

| Category             |   Stage    | Treatment                  |
|----------------------|:----------:|:---------------------------|
| [Superficial Tumors] |    T1a     | Endoscopic Therapy         |
| [Localized Tumors]   |   T1b T2   | Surgery                    |
| [Locally advanced]   | T3 or N^+^ | Chemo$\pm$ RT → Surgery    |
| [Metastatic]         |     M1     | Chemotherapy +/- Radiation |

## Superficial Tumors

-   Endoscopic Ultrasound
-   Endoscopic Mucosal Resection
    -   Diagnostic (T staging)
    -   May be therapeutic for T1a tumors

::: notes
Here are my presentation notes!
:::

## Endoscopic Musocal Resection

::::: {.columns align="center"}
::: {.column width="50%"}
![T1 Tumor](images/t1a_nolabel.png){fig-align="center"}
:::

::: {.column width="50%"}
![Saline Lift](images/t1a_lift2.png){fig-align="center"}
:::
:::::

## Endoscopic Musocal Resection

::::: {.columns align="center"}
::: {.column width="50%"}
![Snare Excision](images/tumor_EMR_snare.png){fig-align="center"}
:::

::: {.column width="50%"}
![](images/t1a_postemr.png){fig-align="center"}
:::
:::::

## EMR Favorable Features

::::: {.columns align="center"}
::: {.column width="50%"}
-   Clear Margins

-   Size \<2cm

-   No LVI/PNI

-   Well-differentiated

-   Overall good prognosis

-   EGD in 6 months for surveillance
:::

::: {.column width="50%"}
![](images/emr_favorable_zoom.png){fig-align="center"}
:::
:::::

## EMR Unfavorable Features

::::: {.columns align="center"}
::: {.column width="50%"}
-   Involved Margins

-   Size \>2cm

-   Lymphovascular/Perineural Invasion

-   Poorly differentiated

-   High risk for recurrence

-   EGD in 3 months for surveillance
:::

::: {.column width="50%"}
![](images/EMR_unfavorable_zoom.png){fig-align="center"}
:::
:::::

## EMR Deep Positive Margin

::::: {.columns align="center"}
::: {.column width="60%"}
Positive deep margin on EMR: likely understaged.

High risk of lymph node metastasis

Recommendation for Surgery
:::

::: {.column width="40%"}
![](images/EMR_Positive_Deep.png){fig-align="center"}
:::
:::::

## Localized Tumors

uT2 N0 are candidates for primary surgery. *However:*

-   EUS has a 25% rate of understaging uT2 N0 tumors
-   Understaged patients treated with surgery need chemo or chemoRT postop

## Asymptomatic Esophageal Tumors (minimal dysphagia)

-   EUS to distinguish T2 from T3 tumors
-   uT2 N0 $\rightarrow$ CT chest/abdomen/pelvis $\rightarrow$ Esophagectomy
-   uT3 or N1 $\rightarrow$ PET $\rightarrow$ neoadjuvant therapy

Patients with dysphagia almost always are T3 tumors (and don't need EUS)

## Symptomatic Esophageal Tumors (dysphagia)

Patients with:

-   Dysphagia to solids
-   Weight loss
-   Tumor length \>3cm are unlikely to have T1-2 tumors

$\Rightarrow$ Initial evaluation with PET

## EUS in Patients with Dysphagia

Memorial Sloan Kettering patients with esophageal cancer:

-   61 with dysphagia, 54 (89%) were found on EUS to have uT3-4 tumors.
-   53 without dysphagia, 25 (47%) were uT1-2 $\rightarrow$ candidates for primary surgery.

EUS can be omitted for patients with dysphagia,

but is useful in those *without* dysphagia.

::: aside
[@ripley226]
:::

## Squamous Cell Carcinoma

::::: {.columns align="center"}
::: {.column width="45%"}
Standard Treatment: ChemoRT (CROSS)

-   Weekly Carboplatin + Paclitaxel
-   5040 cGy radiation in 28 fractions

CROSS: 49% pCR for squamous cell

$\Rightarrow$ Majority never need surgery
:::

::: {.column width="55%"}
![Surgery vs ChemoRT$\rightarrow$ (Squamous Cell is dotted lines)](images/shapiro_1090_fig2b.png){fig-align="center"}
:::
:::::


## Squamous Cell Carcinoma

::::: {.columns align="center"}
::: {.column width="45%"}
Standard Treatment: ChemoRT (CROSS)

-   Weekly Carboplatin + Paclitaxel
-   5040 cGy radiation in 28 fractions

Definitive and Neoadjuvant RT doses are similar except for tumors at the thoracic inlet (wich behave similar to head and neck SCCa)
:::

::: {.column width="55%"}
![Surgery vs ChemoRT$\rightarrow$ (Squamous Cell is dotted lines)](images/shapiro_1090_fig2b.png){fig-align="center"}
:::
:::::

## Restaging after ChemoRT - Squamous Cell

![](images/CRT_surgical_candidate.jpg){fig-align="left"}

## ChemoRT $\rightarrow$ Immediate Surgery? - Squamous Cell
\

Difficult to justify immediate surgery in *all* squamous cell with 50% pCR rate

\

Immediate surgery is considered for fit patients with distal lesions

## EGD for Restaging after ChemoRT - Squamous Cell

![EGD at 6 weeks and 12 weeks](images/CRT_restaging_EGD.jpg){fig-align="left"}

## Positive EGD after ChemoRT - Squamous Cell

These patients will need surgery or systemic therapy

![ChemoRT $\rightarrow$ EGD Positive](images/CRT_restaging_EGD_pos.jpg){fig-align="left"}

## Negative EGD after ChemoRT - Squamous Cell

Most patients with SCCa will have negative EGD after ChemoRT

![ChemoRT $\rightarrow$ EGD Negative](images/CRT_restaging_EGD_neg.jpg){fig-align="left"}

## Active Surveillance for SCCa Esophagus

![ChemoRT $\rightarrow$ EGD Negative $\rightarrow$ Active Surveillance](images/CRT_AS_outcome_SCCA.jpg){fig-align="left"}

## SANO Surveillance Schema

![](images/SANO_schema_notext.jpg){fig-align="left"}

::: aside
[@vanderwilkS1470]
:::

## SANO Surveillance Schema

![](images/SANO_schema_text.jpg){fig-align="left"}

::: aside
[@vanderwilkS1470]
:::

## Adenocarcinoma

::::: {.columns align="center"}
::: {.column width="40%"}
CROSS: benefit from preoperative ChemoRT is less dramatic with adenocarcinoma
:::

::: {.column width="60%"}
![Surgery vs ChemoRT (Adenocarcinoma is solid lines)](images/shapiro_1090_fig2b.png){fig-align="center"}
:::
:::::

## CROSS Treatment Failures

Primary benefit of ChemoRT is reducing locoregional and mixed failures

![](images/eyck_modified.png){fig-align="left"}

::: aside
[@shapiro1090]
:::

## ESOPEC: Periop Chemo (FLOT) vs ChemoRT (CROSS)

![](images/ESOPEC_survival_modified.png){fig-align="left"}

::: aside
[@hoeppner323]
:::

## Locally Advanced Adenocarcinoma

::::: columns
::: {.column width="50%"}
**Chemo + Radiation (CROSS)**

-   Better tolerated
-   Port usually placed
-   More dysphagia (last 2 weeks of Tx)
-   Dysphagia resolves 2-3 weeks later
-   More likely to need feeding tube
:::

::: {.column width="50%"}
**Chemotherapy (FLOT)**

-   More effective (ESOPEC)
-   More toxicity (neutropenia)
-   Port always required
-   Eating slowly improves
-   Less likely to need feeding tube
:::
:::::

## Restaging Scans after ChemoRT - Adenocarcinoma

![Restaging after ChemoRT](images/CRT_surgical_candidate.jpg){fig-align="left"}


## Treatment after Neoadjuvant Therapy - Adenocarcinoma

\
Fit Patients: Recommendation for surgery

\
Adenocarcinoma is not as sensitive to neoadjuvant therapy as squamous cell

## Treatment after Neoadjuvant Therapy - Adenocarcinoma

\
Frail Patients: Restage with EGD

  - If EGD biopsies positive $\rightarrow$ Surgery or systemic therapy
  - If EGD biopsies negative $\rightarrow$ Active Surveillance

## Active Surveillance for Adenocarcinoma after ChemoRT

![](images/CRT_AS_outcome_ACA.jpg){fig-align="left"}

## Esophagectomy at Carolinas Medical Center

-   Minimally-invasive approach (Laparoscopic/VATS $\rightarrow$ Robotic)
-   500+ cases since 2007 (JCS)
-   Anastomotic leak 8%
-   90-day mortality 5.5%
-   Hospital stay 8 days (median)

::: aside
[@lorimer177]
:::

## Frailty Assessment

![Grip Strength $\rightarrow$ CT Body Composition for evaluation of frailty](images/CMC_slides/HGS_CT.png){fig-align="left"}

::: aside
[@colcord3040]
:::

## Body Composition and Age Predict Operative Mortality

![90-day mortality after esophagectomy=$f$(age + body composition)](images/CMC_slides/BC_90Day_XY.png){height=740}

::: aside
[@sanderfer]
:::

## Body Composition and Age Predict Operative Mortality

![90-day mortality esophagectomy =$f$(age + body composition)](images/CMC_slides/BC_90Day_Matrix.png){fig-align="left"}

## Can Body Composition Predict Benefit of Surgery?

316 esophageal cancer treated initially with chemo + radiation​

-   Surgery in 254
-   No surgery in 62

Cohort stratified by age and body composition

-   Low Risk (Lower risk 75%)
-   High Risk (Higher risk 25%)

## Survival Benefit of Surgery - Normal Muscle

![Surgical Risk =$f(age + body composition)$](images/CMC_slides/LowRisk_label.png){height=740}

::: aside
[@sanderferb]
:::




## Survival Benefit of Surgery - Low Muscle

![Surgical Risk =$f(age + body composition)$](images/CMC_slides/HighRisk_label.png){height=740}


::: aside
[@sanderferb]
:::


##  {background-color="#b2b2b2"}

## Locally Advanced

Treatment depends upon histology:

[Squamous Cell Carcinoma]

[Adenocarcinoma]

## Metastatic

FOLFOX is first-line systemic therapy for metastatic GI cancers

-   Dose-limiting toxicity is frequently peripheral neuropathy

## References
